ATYR Reiterate Overweight and $7 PT as EFZO-FIT Posthoc Analysis Further Supports Ph3 Restrictive Patient Selection @ Piper
ATYR Reiterate Overweight and $7 PT as EFZO-FIT Posthoc Analysis Further Supports Ph3 Restrictive Patient Selection @ Piper
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.